Mural Oncology (MURA) said Tuesday it plans to explore strategic alternatives following a review of data from its phase 2 trial in melanoma and previously announced results from the phase 3 trial in platinum-resistant ovarian cancer.
The company said it is discontinuing all clinical development of nemvaleukin alfa and cutting its workforce by about 90%.
Mural said it has hired Lucid Capital Markets to serve as its financial adviser in connection with the exploration of strategic alternatives, adding that there was no assurance that the process will lead to any transaction.
The company said it has not received any approaches and was not in active discussions with any potential suitor.
Mural Oncology climbed by more than 95% in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。